PDF(Pubmed)
Abstract：
UNASSIGNED: In recent years, various novel surgical and non-surgical therapeutic options have been developed for treating obesity. Due to its disputed success, intragastric botulinum toxin A (BTX-A) injection is still being debated.
UNASSIGNED: We aim to contribute to this controversial issue in the literature by sharing our center\'s findings regarding intragastric BTX-A injections in the treatment of obesity.
UNASSIGNED: Patients with a body mass index (BMI) of greater than 25 kg/m2 and at least one obesity-related complication, or a BMI of greater than 30 kg/m2 without complications, were eligible for the study if they were between the ages of 18 and 65.
UNASSIGNED: Following the same procedure, two endoscopists administered BTX-A to all patients. All patients were evaluated for obesity by measuring their lipid profile, hormone profile, and insulin resistance level before treatment.
UNASSIGNED: In our study on 82 patients, we saw a significant mean weight loss (-9.2 kg, p < 0.001) in the second month, and there was no additional mean weight loss in the sixth month of follow-up. In addition, this result seems to be independent of the patient\'s insulin resistance. We did not see any serious side effects in any of the patients.
UNASSIGNED: Although the use of intragastric injection of BTX-A in the treatment of obesity is a controversial issue, we showed in our study that it causes significant weight loss. Further studies are needed on this subject, as it can be a safe method when the ideal dose and application site are combined with appropriate patient selection.
UNASSIGNED: We aim to contribute to this controversial issue in the literature by sharing our center\'s findings regarding intragastric BTX-A injections in the treatment of obesity.
UNASSIGNED: Patients with a body mass index (BMI) of greater than 25 kg/m2 and at least one obesity-related complication, or a BMI of greater than 30 kg/m2 without complications, were eligible for the study if they were between the ages of 18 and 65.
UNASSIGNED: Following the same procedure, two endoscopists administered BTX-A to all patients. All patients were evaluated for obesity by measuring their lipid profile, hormone profile, and insulin resistance level before treatment.
UNASSIGNED: In our study on 82 patients, we saw a significant mean weight loss (-9.2 kg, p < 0.001) in the second month, and there was no additional mean weight loss in the sixth month of follow-up. In addition, this result seems to be independent of the patient\'s insulin resistance. We did not see any serious side effects in any of the patients.
UNASSIGNED: Although the use of intragastric injection of BTX-A in the treatment of obesity is a controversial issue, we showed in our study that it causes significant weight loss. Further studies are needed on this subject, as it can be a safe method when the ideal dose and application site are combined with appropriate patient selection.
摘要：
■近年来，已经开发了各种新颖的手术和非手术治疗方案来治疗肥胖症.由于它有争议的成功，胃内肉毒毒素A（BTX-A）注射仍在争论中。
■我们的目标是通过分享我们中心关于胃内注射BTX-A治疗肥胖的研究结果，为文献中这个有争议的问题做出贡献。
■体重指数（BMI）大于25kg/m2且至少有一种肥胖相关并发症的患者，或BMI大于30kg/m2，无并发症，如果他们年龄在18到65岁之间，就有资格参加这项研究。
■按照相同的步骤，两名内镜医师对所有患者给予BTX-A。通过测量他们的血脂谱来评估所有患者的肥胖，激素谱,治疗前胰岛素抵抗水平。
■在我们对82名患者的研究中，我们看到了显著的平均体重减轻(-9.2公斤，p<0.001)在第二个月，在随访的第6个月没有额外的平均体重减轻。此外,这个结果似乎与患者的胰岛素抵抗无关。我们没有在任何患者中看到任何严重的副作用。
■尽管在治疗肥胖症中使用BTX-A胃内注射是一个有争议的问题，我们在研究中表明，它会导致明显的体重减轻。这个问题需要进一步的研究，因为当理想的剂量和应用部位与适当的患者选择相结合时，它可能是一种安全的方法。
■我们的目标是通过分享我们中心关于胃内注射BTX-A治疗肥胖的研究结果，为文献中这个有争议的问题做出贡献。
■体重指数（BMI）大于25kg/m2且至少有一种肥胖相关并发症的患者，或BMI大于30kg/m2，无并发症，如果他们年龄在18到65岁之间，就有资格参加这项研究。
■按照相同的步骤，两名内镜医师对所有患者给予BTX-A。通过测量他们的血脂谱来评估所有患者的肥胖，激素谱,治疗前胰岛素抵抗水平。
■在我们对82名患者的研究中，我们看到了显著的平均体重减轻(-9.2公斤，p<0.001)在第二个月，在随访的第6个月没有额外的平均体重减轻。此外,这个结果似乎与患者的胰岛素抵抗无关。我们没有在任何患者中看到任何严重的副作用。
■尽管在治疗肥胖症中使用BTX-A胃内注射是一个有争议的问题，我们在研究中表明，它会导致明显的体重减轻。这个问题需要进一步的研究，因为当理想的剂量和应用部位与适当的患者选择相结合时，它可能是一种安全的方法。
